Table 1. Baseline characteristics of ACS baseline, ACS follow-up and non-ACS patients.
ACS, acute coronary syndrome; FU, follow-up; BMI, Body Mass Index; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; TIA, transient ischemic attack, ACE, angiotensin-converting enzyme; ATII, angiotensin II receptor antagonist; TnT, Troponin T; hsTnT, high-sensitivity Troponin T; CK, creatinine kinase; LDH, lactate dehydrogenase; ASAT, aspartate aminotransferase; CRP, C-reactive protein. Continuous data are presented as mean ± SD or median ± IQR and statistical analysis of continuous data was performed using unpaired Student’s t-test or Mann-Whitney U test. Categorical variables are presented as %, with differences between the groups tested with χ². P-value1: ACS baseline vs. non-ACS patients; P-value2: ACS baseline vs. ACS follow-up patients.
| ACS Baseline (n = 104) | Non-ACS (n = 42) | ACS Follow-up (n = 73) | P-value1 | P-value2 | |
|---|---|---|---|---|---|
| Age, yrs (range) | 67 (42–100) | 62 (31–88) | 66 (42–100) | 0.035 | 0.744 |
| Sex, m (%) | 71 (68.3) | 23 (54.8) | 54 (74.0) | 0.129 | 0.412 |
| BMI, kg/m2 | 26.3 (24.2–29.1) | 28.0 (26.0–30.9) | 26.3 (24.2–29.4) | 0.169 | 0.970 |
| Smoking status, n (%) | |||||
| Current | 20 (19.2) | 8 (19.0) | 14 (9.2) | 0.979 | 0.993 |
| Former | 59 (56.7) | 20 (47.6) | 48 (65.8) | 0.317 | 0.227 |
| Family history of CAD | 39 (37.5) | 15 (35.7) | 29 (35.7) | 0.839 | 0.764 |
| Medical history | |||||
| Hypertension, n (%) | 44 (42.3) | 17 (40.5) | 26 (35.6) | 0.839 | 0.370 |
| Diabetes type II, n (%) | 16 (15.4) | 4 (9.5) | 11 (15.1) | 0.351 | 0.954 |
| Hypercholesterolemia, n (%) | 43 (41.3) | 16 (38.1) | 27 (37.0) | 0.717 | 0.559 |
| Myocardial infarction, n (%) | 18 (17.3) | 7 (16.7) | 13 (17.8) | 0.926 | 0.931 |
| PCI, n (%) | 18 (17.3) | 9 (21.4) | 13 (17.8) | 0.562 | 0.931 |
| CABG, n (%) | 10 (9.6) | 2 (4.8) | 9 (12.3) | 0.334 | 0.566 |
| Claudication, n (%) | 2 (1.9) | 0 (0.0) | 2 (2.7) | 0.366 | 0.719 |
| Stroke/TIA, n (%) | 8 (7.7) | 3 (7.1) | 5 (6.8) | 0.909 | 0.832 |
| Medication | |||||
| Platelet inhibitors | |||||
| Aspirin | 39 (37.5) | 15 (35.7) | 26 (35.6) | 0.839 | 0.798 |
| Clopidogrel | 8 (7.7) | 3 (7.1) | 6 (8.2) | 0.909 | 0.898 |
| Dipyridamole | 2 (1.9) | 1 (2.4) | 1 (1.4) | 0.859 | 0.779 |
| Antihypertensive agents | |||||
| ACE-inhibitor | 10 (9.6) | 7 (16.7) | 9 (12.3) | 0.229 | 0.566 |
| ATII-antagonist | 16 (15.4) | 2 (4.8) | 10 (13.7) | 0.077 | 0.755 |
| Calcium antagonist | 16 (15.4) | 6 (14.3) | 12 (16.4) | 0.867 | 0.850 |
| Diuretic | 18 (17.3) | 6 (14.3) | 11 (15.0) | 0.656 | 0.692 |
| Nitrate | 15 (14.4) | 5 (11.9) | 10 (13.7) | 0.689 | 0.892 |
| β-blocker | 32 (30.8) | 9 (21.4) | 20 (27.4) | 0.256 | 0.628 |
| Statins | 41 (39.4) | 15 (35.7) | 26 (35.6) | 0.677 | 0.607 |
| Laboratory measures | |||||
| Troponin | |||||
| TnT (0.01–0.1 μg/L) | 0.87 (0.03–6.72) | 0.0 (0.0–0.0) | 1.21 (0.06–9.60) | <0.0001 | 0.456 |
| hsTnT (3–14 ng/L) | 42 (16–255) | 8.0 (4.0–12.0) | 42 (16–228) | <0.0001 | 0.959 |
| CK (♂<225, ♀<160 U/L) | 179 (97–453) | 95 (62–142) | 177 (80–445) | <0.0001 | 0.548 |
| LDH (<480 U/L) | 211 (171–258) | 187 (163–242) | 211 (172–245) | 0.256 | 0.924 |
| ASAT (<35 U/L) | 35 (25–75) | 24 (20–33) | 36 (25–75) | <0.0001 | 0.828 |
| CRP (<10 mg/L) | 4.0 (2.0–9.0) | 2.0 (0.0–2.0) | 4.0 (2.0–8.3) | 0.002 | 0.943 |
| Glucose (<7.8 mmol/L) | 7.0 (6.1–8.6) | 6.3 (5.4–6.7) | 6.9 (6.0–8.3) | 0.002 | 0.593 |
| Creatinine (♂<110, ♀<95 μmol/L) | 76 (66–86) | 79 (65–92) | 76 (68–87) | 0.753 | 0.750 |